massachusetts_institute_of_technology_7194419730

Novo joins forces with MIT innovating drug devices

pharmafile | September 8, 2015 | News story | Manufacturing and Production, Research and Development Novo Nordisk 

Novo Nordisk has initiated a research collaboration with the Langer Laboratory at the Massachusetts Institute of Technology for what is thought to be the next generation of drug delivery devices for the administration of peptides. 

The aim of the research collaboration, which is conducted at both MIT in Boston, US and at Novo Nordisk’s research facilities in Måløv and Hillerød, Denmark, is to develop the next generation of drug delivery devices as an alternative to parenteral or injection-based delivery of peptides.

Peter Kurtzhals, senior vice president and head of global research at Novo Nordisk says: “Drug delivery devices hold great potential and I am looking forward to this exciting research collaboration with one of the world’s leading drug delivery laboratories,”

Professor Robert Langer’s laboratory at MIT are world-leading experts in creating new approaches for delivering drugs such as peptides and proteins across complex barriers in the body such as the blood-brain barrier, the intestine, the lung and the skin. Together with Dr Giovanni Traverso, a gastroenterologist and biomedical engineer at Harvard Medical School, and research affiliate of MIT, they will lead a team in the development of a platform enabling the oral delivery of peptides.  

Robert Langer, professor and head of the Langer Laboratory at MIT, says: “We are very excited to be doing research sponsored by Novo Nordisk to address one of the current greatest challenges in drug delivery”.

Yasmita Kumar

Related Content

CHMP recommends Novo Nordisk’s Awiqli for diabetes treatment

Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for …

Almirall licenses Novo Nordisk’s anti-IL-21 monoclonal antibody for dermatology treatment

Almirall has announced that it has entered into an exclusive license agreement with Novo Nordisk …

Novo Nordisk shares positive results from COMBINE 3 phase 3a trial

Novo Nordisk has shared topline results from the COMBINE 3 phase 3a trial of once-weeklly …

Latest content